BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27272783)

  • 1. Novel Tumor-specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-regulated Kinase Activity.
    Serizawa M; Kusuhara M; Ohnami S; Nagashima T; Shimoda Y; Ohshima K; Mochizuki T; Urakami K; Yamaguchi K
    Anticancer Res; 2016 Jun; 36(6):2733-44. PubMed ID: 27272783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
    Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
    Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinases: from biology to pathology.
    Choura M; Rebaï A
    J Recept Signal Transduct Res; 2011 Dec; 31(6):387-94. PubMed ID: 22040163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.
    Zarei O; Benvenuti S; Ustun-Alkan F; Hamzeh-Mivehroud M; Dastmalchi S
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2429-2446. PubMed ID: 27503093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
    Ghosh S; Marrocco I; Yarden Y
    Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.
    Fan Y; Arechederra M; Richelme S; Daian F; Novello C; Calderaro J; Di Tommaso L; Morcrette G; Rebouissou S; Donadon M; Morenghi E; Zucman-Rossi J; Roncalli M; Dono R; Maina F
    Hepatology; 2017 Nov; 66(5):1644-1661. PubMed ID: 28586114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
    O'Farrell AM; Foran JM; Fiedler W; Serve H; Paquette RL; Cooper MA; Yuen HA; Louie SG; Kim H; Nicholas S; Heinrich MC; Berdel WE; Bello C; Jacobs M; Scigalla P; Manning WC; Kelsey S; Cherrington JM
    Clin Cancer Res; 2003 Nov; 9(15):5465-76. PubMed ID: 14654525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types.
    Grillo E; Ravelli C; Corsini M; Gaudenzi C; Zammataro L; Mitola S
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166313. PubMed ID: 34826586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.
    Keppler S; Weiβbach S; Langer C; Knop S; Pischimarov J; Kull M; Stühmer T; Steinbrunn T; Bargou R; Einsele H; Rosenwald A; Leich E
    Oncotarget; 2016 Jun; 7(25):38762-38774. PubMed ID: 27246973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of receptor tyrosine kinase activation in cancer.
    Du Z; Lovly CM
    Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase receptors as attractive targets of cancer therapy.
    Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
    Kleczko EK; Heasley LE
    Mol Cancer; 2018 Feb; 17(1):60. PubMed ID: 29458371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.